{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:18:18Z","timestamp":1790097498230,"version":"4.0.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS097901"],"award-info":[{"award-number":["R01 NS097901"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS107539"],"award-info":[{"award-number":["R01NS107539"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson&apos;s Research","doi-asserted-by":"publisher","award":["020600"],"award-info":[{"award-number":["020600"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["T32GM105538"],"award-info":[{"award-number":["T32GM105538"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Haloperidol is used to manage psychotic symptoms in several neurological disorders through mechanisms that involve antagonism of dopamine D2 receptors that are highly expressed in the striatum. Significant side effects of haloperidol, known as extrapyramidal symptoms, lead to motor deficits similar to those seen in Parkinson\u2019s disease and present a major challenge in clinical settings. The underlying molecular mechanisms responsible for these side effects remain poorly understood. Parkinson\u2019s disease-associated leucine-rich repeat kinase 2 (LRRK2) has an essential role in striatal physiology and a known link to dopamine D2 receptor signaling. Here, we systematically explore convergent signaling of haloperidol and LRRK2 through pharmacological or genetic inhibition of LRRK2 kinase, as well as knock-in mouse models expressing pathogenic mutant LRRK2 with increased kinase activity. Behavioral assays show that LRRK2 kinase inhibition ameliorates haloperidol-induced motor changes in mice. A combination of electrophysiological and anatomical approaches reveals that LRRK2 kinase inhibition interferes with haloperidol-induced changes, specifically in striatal neurons of the indirect pathway. Proteomic studies and targeted intracellular pathway analyses demonstrate that haloperidol induces a similar pattern of intracellular signaling as increased LRRK2 kinase activity. Our study suggests that LRRK2 kinase plays a key role in striatal dopamine D2 receptor signaling underlying the undesirable motor side effects of haloperidol. This work opens up new therapeutic avenues for dopamine-related disorders, such as psychosis, also furthering our understanding of Parkinson\u2019s disease pathophysiology.<\/jats:p>","DOI":"10.1038\/s41380-025-03030-z","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:40:24Z","timestamp":1745419224000},"page":"4473-4486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-5173","authenticated-orcid":false,"given":"Chuyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2696-3265","authenticated-orcid":false,"given":"Meghan","family":"Masotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-3152","authenticated-orcid":false,"given":"Nathaniel","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9078-6232","authenticated-orcid":false,"given":"Vanessa","family":"Promes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-8050","authenticated-orcid":false,"given":"Giulia","family":"Tombesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-830X","authenticated-orcid":false,"given":"Daniel","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5367-4023","authenticated-orcid":false,"given":"Claudia","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8172-3598","authenticated-orcid":false,"given":"Elisa","family":"Greggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-7682","authenticated-orcid":false,"given":"Sabine","family":"Hilfiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3710-1484","authenticated-orcid":false,"given":"Yevgenia","family":"Kozorovitskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-4200","authenticated-orcid":false,"given":"Loukia","family":"Parisiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"3030_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"JM Beaulieu","year":"2011","unstructured":"Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63:182\u2013217. https:\/\/doi.org\/10.1124\/pr.110.002642.","journal-title":"Pharmacol Rev"},{"key":"3030_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/rrs-00029981","volume":"24","author":"KA Neve","year":"2004","unstructured":"Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res. 2004;24:165\u2013205. https:\/\/doi.org\/10.1081\/rrs-00029981.","journal-title":"J Recept Signal Transduct Res"},{"key":"3030_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annrev-neuro-061010-113641","volume":"34","author":"CR Gerfen","year":"2011","unstructured":"Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci. 2011;34:441\u201366. https:\/\/doi.org\/10.1146\/annrev-neuro-061010-113641.","journal-title":"Annu Rev Neurosci"},{"key":"3030_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.neuron.2008.11.005","volume":"60","author":"AC Kreitzer","year":"2008","unstructured":"Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron. 2008;60:543\u201354. https:\/\/doi.org\/10.1016\/j.neuron.2008.11.005.","journal-title":"Neuron"},{"key":"3030_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-v","volume":"13","author":"MR Delong","year":"1990","unstructured":"Delong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13:281\u20135. https:\/\/doi.org\/10.1016\/0166-2236(90)90110-v.","journal-title":"Trends Neurosci"},{"key":"3030_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/0166-2236(90)90107-I","volume":"13","author":"GE Alexander","year":"1990","unstructured":"Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990;13:266\u201371. https:\/\/doi.org\/10.1016\/0166-2236(90)90107-I.","journal-title":"Trends Neurosci"},{"key":"3030_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00702-019-01997-y","volume":"126","author":"S Zhai","year":"2019","unstructured":"Zhai S, Shen W, Graves SM, Surmeier JD. Dopaminergic modulation of striatal function and Parkinson\u2019s disease. J Neural Transm. 2019;126:411\u201322. https:\/\/doi.org\/10.1007\/s00702-019-01997-y.","journal-title":"J Neural Transm"},{"key":"3030_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-020-03050-5","volume":"590","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Lodder B, Chen Y, Patriarchi T, Tian L, Sabatini B. Cell-type-specific asynchronous modulation of PKA by dopamine in learning. Nature. 2020;590:451\u20136. https:\/\/doi.org\/10.1038\/s41586-020-03050-5.","journal-title":"Nature"},{"key":"3030_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41586-022-05407-4","volume":"611","author":"L Ma","year":"2022","unstructured":"Ma L, Day-Cooney J, Benavides O, Muniak MA, Qin M, Ding J, et al. Locomotion activates PKA through dopamine and adenosine in striatal neurons. Nature. 2022;611:762\u20138. https:\/\/doi.org\/10.1038\/s41586-022-05407-4.","journal-title":"Nature"},{"key":"3030_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11846","volume":"494","author":"G Cui","year":"2013","unstructured":"Cui G, Jun SB, Jin X, Pham MD, Vogel SS, Lovinger D, et al. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature. 2013;494:238\u201342. https:\/\/doi.org\/10.1038\/nature11846.","journal-title":"Nature"},{"key":"3030_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481\u20133. https:\/\/doi.org\/10.1126\/science3854.","journal-title":"Science"},{"key":"3030_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/261717a0","volume":"261","author":"P Seeman","year":"1976","unstructured":"Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic\/dopamine receptors. Nature. 1976;261:717\u20139. https:\/\/doi.org\/10.1038\/261717a0.","journal-title":"Nature"},{"key":"3030_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/JCP.0b013e3181f14098","volume":"30","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30:531\u201340. https:\/\/doi.org\/10.1097\/JCP.0b013e3181f14098.","journal-title":"J Clin Psychopharmacol"},{"key":"3030_CR14","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","volume":"28","author":"S Siafis","year":"2023","unstructured":"Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023;28:3267\u201377. https:\/\/doi.org\/10.1038\/s41380-023-02203-y.","journal-title":"Mol Psychiatry"},{"key":"3030_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/35041572","volume":"9","author":"A Usiello","year":"2000","unstructured":"Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000;9:199\u2013203. https:\/\/doi.org\/10.1038\/35041572.","journal-title":"Nature"},{"key":"3030_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/npp.2016.173","volume":"42","author":"LE Sebel","year":"2017","unstructured":"Sebel LE, Graves SM, Chan CS, Surmeier JD. Haloperidol selectively remodels striatal indirect pathway circuits. Neuropsychopharmacology. 2017;42:963\u201373. https:\/\/doi.org\/10.1038\/npp.2016.173.","journal-title":"Neuropsychopharmacology"},{"key":"3030_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41531-023-00544-7","volume":"9","author":"JM Taymans","year":"2023","unstructured":"Taymans JM, Fell M, Greenmamyre T, Hirst WD, Mamais A, Padmanabhan S, et al. Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis. 2023;9:104. https:\/\/doi.org\/10.1038\/s41531-023-00544-7.","journal-title":"NPJ Parkinsons Dis"},{"key":"3030_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1126\/science.aar5683","volume":"360","author":"DR Alessi","year":"2018","unstructured":"Alessi DR, Sammler E. LRRK2 kinase in Parkinson\u2019s disease. Science. 2018;360:36\u20137. https:\/\/doi.org\/10.1126\/science.aar5683.","journal-title":"Science"},{"key":"3030_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.tibs.221.10.003","volume":"47","author":"V Tokars","year":"2022","unstructured":"Tokars V, Chen C, Parisiadou L. Closing the structure-to-function gap for LRRK2. Trends Biochem Sci. 2022;47:187\u20138. https:\/\/doi.org\/10.1016\/j.tibs.221.10.003.","journal-title":"Trends Biochem Sci"},{"key":"3030_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nn3636","volume":"17","author":"L Parisiadou","year":"2014","unstructured":"Parisiadou L, Yu J, Sgobio C, Xie C, Liu G, Sun L, et al. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci. 2014;17:367\u201376. https:\/\/doi.org\/10.1038\/nn3636.","journal-title":"Nat Neurosci"},{"key":"3030_CR21","doi-asserted-by":"publisher","first-page":"7128","DOI":"10.1523\/JNEROSCI.3314-15.2016","volume":"36","author":"BA Matikainen-Ankney","year":"2016","unstructured":"Matikainen-Ankney BA, Kezunovic N, Mesias RE, Tian Y, Williams FM, Huntley GW, et al. Altered development of synapse structure and function in striatum caused by Parkinson\u2019s disease-linked LRRK2-G2019S mutation. J Neurosci. 2016;36:7128\u201341. https:\/\/doi.org\/10.1523\/JNEROSCI.3314-15.2016.","journal-title":"J Neurosci"},{"key":"3030_CR22","doi-asserted-by":"publisher","first-page":"9700","DOI":"10.1523\/JNEUROSCI.1457-18.2018","volume":"38","author":"BA Matikainen-Ankney","year":"2018","unstructured":"Matikainen-Ankney BA, Kezunovic N, Menard C, Flanigan M, Zhong Y, Russo SJ, et al. Parkinson\u2019s disease-linked LRRK2-G2019S mutation alters synaptic plasticity and promotes resilience to chronic social stress in young adulthood. J Neurosci. 2018;38:9700\u201311. https:\/\/doi.org\/10.1523\/JNEUROSCI.1457-18.2018.","journal-title":"J Neurosci"},{"key":"3030_CR23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s42003-022-04136-8","volume":"5","author":"HS Xenias","year":"2022","unstructured":"Xenias HS, Chen C, Kang S, Cherian S, Situ X, Shanmugasundaram B, et al. R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations. Commun Biol. 2022;5:1211. https:\/\/doi.org\/10.1038\/s42003-022-04136-8.","journal-title":"Commun Biol"},{"key":"3030_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/cells11010169","volume":"11","author":"PD Skelton","year":"2022","unstructured":"Skelton PD, Tokars V, Parisiadou L. LRRK2 at striatal synapses: cell-type specificity and mechanistic insights. Cells. 2022;11:169. https:\/\/doi.org\/10.3390\/cells11010169.","journal-title":"Cells"},{"key":"3030_CR25","doi-asserted-by":"publisher","first-page":"e28377","DOI":"10.7554\/eLife28377","volume":"6","author":"M Volta","year":"2017","unstructured":"Volta M, Beccano-Kelly DA, Paschall SA, Cataldi S, MacIsaac SE, Kuhlmann N, et al. Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice. eLife. 2017;6:e28377. https:\/\/doi.org\/10.7554\/eLife28377.","journal-title":"eLife"},{"key":"3030_CR26","doi-asserted-by":"publisher","first-page":"e58997","DOI":"10.7554\/eLife.58997","volume":"9","author":"C Chen","year":"2020","unstructured":"Chen C, Soto G, Dumrongprechachan V, Bannon N, Kang S, Kozorovitskiy Y, et al. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations. eLife. 2020;9:e58997. https:\/\/doi.org\/10.7554\/eLife.58997.","journal-title":"eLife"},{"key":"3030_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0221-2","volume":"9","author":"A Tozzi","year":"2018","unstructured":"Tozzi A, Tantucci M, Marchi S, Mozzocchetti P, Morari M, Pinton P, et al. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson\u2019s disease. Cell Death Dis. 2018;9:204. https:\/\/doi.org\/10.1038\/s41419-017-0221-2.","journal-title":"Cell Death Dis"},{"key":"3030_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2018.06.008","volume":"118","author":"A Tozzi","year":"2018","unstructured":"Tozzi A, Durante V, Bastioli G, Mazzocchetti M, Novello S, Mechelli A, et al. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson\u2019s disease. Neurobiol Dis. 2018;118:1\u20138. https:\/\/doi.org\/10.1016\/j.nbd.2018.06.008.","journal-title":"Neurobiol Dis"},{"key":"3030_CR29","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/hmg\/ddu543","volume":"24","author":"DA Beccano-Kelly","year":"2015","unstructured":"Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatamikov I, Co K, et al. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet. 2015;24:1336\u201349. https:\/\/doi.org\/10.1093\/hmg\/ddu543.","journal-title":"Hum Mol Genet"},{"key":"3030_CR30","doi-asserted-by":"publisher","first-page":"e12813","DOI":"10.7554\/eLife.12813","volume":"5","author":"M Steger","year":"2016","unstructured":"Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. eLife. 2016;5:e12813. https:\/\/doi.org\/10.7554\/eLife.12813.","journal-title":"eLife"},{"key":"3030_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","volume":"23","author":"E Greggio","year":"2006","unstructured":"Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, et al. Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin. Neurobiol Dis. 2006;23:329\u201341. https:\/\/doi.org\/10.1016\/j.nbd.2006.04.001.","journal-title":"Neurobiol Dis"},{"key":"3030_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1042\/BST20160238","volume":"45","author":"M Volta","year":"2017","unstructured":"Volta M, Melrose H. LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. Biochem Soc Trans. 2017;45:113\u201322. https:\/\/doi.org\/10.1042\/BST20160238.","journal-title":"Biochem Soc Trans"},{"key":"3030_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.nbd.2015.02.031","volume":"78","author":"M Yue","year":"2015","unstructured":"Yue M, Hinkle K, Davies P, Trushina E, Fiesel F, Christenson T, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:172\u201395. https:\/\/doi.org\/10.1016\/j.nbd.2015.02.031.","journal-title":"Neurobiol Dis"},{"key":"3030_CR34","doi-asserted-by":"publisher","first-page":"14622","DOI":"10.1073\/pnas.0906334106","volume":"106","author":"Y Tong","year":"2009","unstructured":"Tong Y, Pisani A, Martella G, Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA. 2009;106:14622\u20137. https:\/\/doi.org\/10.1073\/pnas.0906334106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3030_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","volume":"355","author":"MJ Fell","year":"2015","unstructured":"Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, et al. MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther. 2015;355:397\u2013409. https:\/\/doi.org\/10.1124\/jpet.115.227587.","journal-title":"J Pharmacol Exp Ther"},{"key":"3030_CR36","doi-asserted-by":"publisher","first-page":"eadk6191","DOI":"10.1126\/sciadv.adk6191","volume":"9","author":"MS Murillo","year":"2023","unstructured":"Murillo MS, Suarez A, Dederer V, Chatterjee D, Louro JA, Knapp S, et al. Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures. Sci Adv. 2023;9:eadk6191. https:\/\/doi.org\/10.1126\/sciadv.adk6191.","journal-title":"Sci Adv"},{"key":"3030_CR37","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","volume":"60","author":"JD Scott","year":"2017","unstructured":"Scott JD, DeMong DE, Greshock TJ, Basu K, Dai X, Harris J, et al. Discovery of a 3-(4-Pyrimidinyl) indazole (MLi-2), an orally available and selective leucine- rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity. J Med Chem. 2017;60:2983\u201392. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00045.","journal-title":"J Med Chem"},{"key":"3030_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13024-021-00441-8","volume":"16","author":"JH Kluss","year":"2021","unstructured":"Kluss JH, Mazza MC, Li Y, Manzoni C, Lewis P, Cookson MR, et al. Preclinical modeling of chronic inhibition of the Parkinson\u2019s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Mol Neurodegener. 2021;16:17. https:\/\/doi.org\/10.1186\/s13024-021-00441-8.","journal-title":"Mol Neurodegener"},{"key":"3030_CR39","doi-asserted-by":"publisher","first-page":"e87098","DOI":"10.7554\/eLife.87098","volume":"12","author":"HS Dhekne","year":"2023","unstructured":"Dhekne HS, Tonelli F, Yeshaw WM, Chiang CY, Linouse C, Jaimon E, et al. Genome-wide screen reveals Rab12 GTPase as a critical activator of Parkinson\u2019s disease-linked LRRK2 kinase. eLife. 2023;12:e87098. https:\/\/doi.org\/10.7554\/eLife.87098.","journal-title":"eLife"},{"key":"3030_CR40","doi-asserted-by":"publisher","first-page":"eaav0820","DOI":"10.1126\/scitranslmed.aav0820","volume":"12","author":"MAS Baptista","year":"2020","unstructured":"Baptista MAS, Merchant K, Barrett T, Bhargava S, Bryce DK, Ellis JM, et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci Transl Med. 2020;12:eaav0820. https:\/\/doi.org\/10.1126\/scitranslmed.aav0820.","journal-title":"Sci Transl Med"},{"key":"3030_CR41","doi-asserted-by":"publisher","unstructured":"Yuan Y, Li H, Sreeram K, Malankhanova T, Boddu R, Strader S, et al. Single molecule array measures of LRRK2 kinase activity in serum link Parkinson\u2019s disease severity to peripheral inflammation. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.04.15.589570.","DOI":"10.1101\/2024.04.15.589570"},{"key":"3030_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87\u201396. https:\/\/doi.org\/10.1016\/0893-133X(94)00129-N.","journal-title":"Neuropsychopharmacology"},{"key":"3030_CR43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.1717194115","volume":"115","author":"D Radl","year":"2018","unstructured":"Radl D, Chiacchiaretta M, Lewis RG, Brami-Cherrier K, Arcuri L, Borelli E. Differential regulation of striatal motor behavior and related cellular responses by dopamine d2l and d2s isoforms. Proc Natl Acad Sci USA. 2018;115:198\u2013203. https:\/\/doi.org\/10.1073\/pnas.1717194115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3030_CR44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2006.04.023","volume":"60","author":"F Gilbert","year":"2006","unstructured":"Gilbert F, Morissette M, Hilaire MST, Paquet B, Rouillard C, DiPaolo T, et al. Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover. Biol Psychiatry. 2006;60:538\u201347. https:\/\/doi.org\/10.1016\/j.biopsych.2006.04.023.","journal-title":"Biol Psychiatry"},{"key":"3030_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0014-2999(77)90325-9","volume":"41","author":"C Ezrin-Waters","year":"1977","unstructured":"Ezrin-Waters C, Seeman P. Tolerance to haloperidol catalepsy. Eur J Pharmacol. 1977;41:321\u20137. https:\/\/doi.org\/10.1016\/0014-2999(77)90325-9.","journal-title":"Eur J Pharmacol"},{"key":"3030_CR46","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41386-020-00799-1","volume":"45","author":"SM Augustin","year":"2020","unstructured":"Augustin SM, Loewinger GC, O\u2019Neal TJ, Kravitz AV, Lovinger DM. Dopamine D2 receptor signaling on iMSNs is required for initiation and vigor of learned actions. Neuropsychopharmacology. 2020;45:2087\u201397. https:\/\/doi.org\/10.1038\/s41386-020-00799-1.","journal-title":"Neuropsychopharmacology"},{"key":"3030_CR47","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.neuron.2016.04.040","volume":"90","author":"JC Lemos","year":"2016","unstructured":"Lemos JC, Friend DM, Kaplan AR, Shin JH, Rubinstein M, Kravitz AV, et al. Enhanced GABA transmission drives bradykinesia following loss of dopamine D2 receptor signaling. Neuron. 2016;90:824\u201338. https:\/\/doi.org\/10.1016\/j.neuron.2016.04.040.","journal-title":"Neuron"},{"key":"3030_CR48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nn.2261","volume":"12","author":"HH Yin","year":"2009","unstructured":"Yin HH, Mulcare SP, Hilario MRF, Clouse E, Holloway T, Davis MI, et al. Dynamic reorganization of striatal circuits during the acquisition and consolidation of a skill. Nat Neurosci. 2009;12:333\u201341. https:\/\/doi.org\/10.1038\/nn.2261.","journal-title":"Nat Neurosci"},{"key":"3030_CR49","doi-asserted-by":"publisher","first-page":"18381","DOI":"10.1523\/JNEUROSCI.1875-13.2013","volume":"33","author":"MK Lobo","year":"2013","unstructured":"Lobo MK, Zaman S, Damez-Werno DM, Wook Koo J, Bagot RC, DiNieri JA, et al. \u0394FosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. J Neurosci. 2013;33:18381\u201395. https:\/\/doi.org\/10.1523\/JNEUROSCI.1875-13.2013.","journal-title":"J Neurosci"},{"key":"3030_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fnsys.2013.00110","volume":"7","author":"D Yael","year":"2013","unstructured":"Yael D, Zeef DH, Sand D, Moran A, Katz DB, Cohen D, et al. Haloperidol-induced changes in neuronal activity in the striatum of the freely moving rat. Front Syst Neurosci. 2013;7:110. https:\/\/doi.org\/10.3389\/fnsys.2013.00110.","journal-title":"Front Syst Neurosci"},{"key":"3030_CR51","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1038\/s41380-021-01235-6","volume":"26","author":"A Kruyer","year":"2021","unstructured":"Kruyer A, Parrilla-Carrero J, Powell C, Brandt L, Gutwinski S, Angelis A, et al. Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity. Mol Psychiatry. 2021;26:6159\u201369. https:\/\/doi.org\/10.1038\/s41380-021-01235-6.","journal-title":"Mol Psychiatry"},{"key":"3030_CR52","doi-asserted-by":"publisher","first-page":"8214","DOI":"10.1523\/JNEUROSCI.1274-04.2004","volume":"24","author":"D Centonze","year":"2004","unstructured":"Centonze D, Usiello A, Costa C, Picconi B, Erbs E, Bernardi G, et al. Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. J Neurosci. 2004;24:8214\u201322. https:\/\/doi.org\/10.1523\/JNEUROSCI.1274-04.2004.","journal-title":"J Neurosci"},{"key":"3030_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev.neuro.23.1.185","volume":"23","author":"SM Nicola","year":"2000","unstructured":"Nicola SM, Surmeier J, Malenka RC. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci. 2000;23:185\u2013215. https:\/\/doi.org\/10.1146\/annurev.neuro.23.1.185.","journal-title":"Annu Rev Neurosci"},{"key":"3030_CR54","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1038\/npp.2011","volume":"36","author":"E Valjent","year":"2011","unstructured":"Valjent E, Bertran-Gonzalez J, Bowling H, Lopez S, Santini E, Matamales M, et al. Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32. Neuropsychopharmacology. 2011;36:2561\u201370. https:\/\/doi.org\/10.1038\/npp.2011.","journal-title":"Neuropsychopharmacology"},{"key":"3030_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuron.2016.06.014","volume":"91","author":"G Kharkwal","year":"2016","unstructured":"Kharkwal G, Brami-Cherrier K, Lizardi-Ortic JE, Nelson A, Ramos M, Del Barrio D, et al. Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons. Neuron. 2016;91:67\u201378. https:\/\/doi.org\/10.1016\/j.neuron.2016.06.014.","journal-title":"Neuron"},{"key":"3030_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02609-w","volume":"13","author":"C Santa","year":"2023","unstructured":"Santa C, Rodrigues D, Coelho JF, Anjo S, Mendes VM, Bessa-Neto B, et al. Chronic treatment with D2-antagonist haloperidol leads to inhibitory\/excitatory imbalance in striatal D1-neurons. Transl Psychiatry. 2023;13:312. https:\/\/doi.org\/10.1038\/s41398-023-02609-w.","journal-title":"Transl Psychiatry"},{"key":"3030_CR57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0304-3940(96)12801-9","volume":"212","author":"SL Eastwood","year":"1996","unstructured":"Eastwood SL, Porter RH, Harrison PJ. The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain. Neurosci Lett. 1996;212:163\u20136. https:\/\/doi.org\/10.1016\/0304-3940(96)12801-9.","journal-title":"Neurosci Lett"},{"key":"3030_CR58","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/0006-8993(89)90867-6","volume":"489","author":"CK Meshul","year":"1989","unstructured":"Meshul CK, Casey DE. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res. 1989;489:338\u201346. https:\/\/doi.org\/10.1016\/0006-8993(89)90867-6.","journal-title":"Brain Res"},{"key":"3030_CR59","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.mcn.2006.05.007","volume":"32","author":"HM Critchlow","year":"2006","unstructured":"Critchlow HM, Maycox PR, Skepper JN, Krylova O. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol Cell Neurosci. 2006;32:356\u201365. https:\/\/doi.org\/10.1016\/j.mcn.2006.05.007.","journal-title":"Mol Cell Neurosci"},{"key":"3030_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0449-7","volume":"12","author":"I Russo","year":"2015","unstructured":"Russo I, Berti G, Plotegher N, Bernardo G, Filograna R, Bubacco L, et al. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-\u03baB p50 signaling in cultured microglia cells. J Neuroinflammation. 2015;12:230. https:\/\/doi.org\/10.1186\/s12974-015-0449-7.","journal-title":"J Neuroinflammation"},{"key":"3030_CR61","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4161\/cib.3.5.12286","volume":"3","author":"L Parisiadou","year":"2010","unstructured":"Parisiadou L, Cai H. LRRK2 function on actin and microtubule dynamics in Parkinson disease. Commun Integr Biol. 2010;3:396\u2013400. https:\/\/doi.org\/10.4161\/cib.3.5.12286.","journal-title":"Commun Integr Biol"},{"key":"3030_CR62","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.neuron.2006.10.008","volume":"52","author":"D MacLeod","year":"2006","unstructured":"MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron. 2006;52:587\u201393. https:\/\/doi.org\/10.1016\/j.neuron.2006.10.008.","journal-title":"Neuron"},{"key":"3030_CR63","doi-asserted-by":"publisher","unstructured":"Tombesi G, Kompella S, Favetta G, Chen C, Zhao Y, Sevegnani M, et al. LRRK2 regulates synaptic function through BDNF signaling and actin cytoskeleton. biorxiv. 2024. https:\/\/doi.org\/10.7554\/eLife.95987.1.","DOI":"10.7554\/eLife.95987.1"},{"key":"3030_CR64","doi-asserted-by":"publisher","first-page":"13971","DOI":"10.1523\/JNEUROSCI.3799-09.2009","volume":"29","author":"L Parisiadou","year":"2009","unstructured":"Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, et al. Phosphorylation of ezrin\/radixin\/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci. 2009;29:13971\u201380. https:\/\/doi.org\/10.1523\/JNEUROSCI.3799-09.2009.","journal-title":"J Neurosci"},{"key":"3030_CR65","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1042\/BST20180469","volume":"46","author":"L Civiero","year":"2018","unstructured":"Civiero L, Cogo S, Biosa A, Greggio E. The role of LRRK2 in cytoskeletal dynamics. Biochem Soc Trans. 2018;46:1653\u201363. https:\/\/doi.org\/10.1042\/BST20180469.","journal-title":"Biochem Soc Trans"},{"key":"3030_CR66","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fnbeh.2017.00240","volume":"11","author":"A De Bartolomeis","year":"2017","unstructured":"De Bartolomeis A, Buonaguro EF, Latte G, Rossi R, Marmo F, Iasevoli F, et al. Immediate-early genes modulation by antipsychotics: translational implications for a putative gateway to drug-induced long-term brain changes. Front Behav Neurosci. 2017;11:240. https:\/\/doi.org\/10.3389\/fnbeh.2017.00240.","journal-title":"Front Behav Neurosci"},{"key":"3030_CR67","doi-asserted-by":"publisher","first-page":"e0118510","DOI":"10.1371\/journal.pone.0118510","volume":"10","author":"K Sakuma","year":"2015","unstructured":"Sakuma K, Komatsu H, Maruyama M, Imaichi S, Habata Y, Mori M. Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain. PLoS ONE. 2015;10:e0118510. https:\/\/doi.org\/10.1371\/journal.pone.0118510.","journal-title":"PLoS ONE"},{"key":"3030_CR68","doi-asserted-by":"publisher","first-page":"11637","DOI":"10.3390\/ijms231911637","volume":"23","author":"O Onimus","year":"2022","unstructured":"Onimus O, Valjent E, Fisone G, Gangarossa G. Haloperidol-induced immediate early genes in striatopallidal neurons requires the converging action of cAMP\/PKA\/DARPP-32 and mTOR pathways. Int J Mol Sci. 2022;23:11637. https:\/\/doi.org\/10.3390\/ijms231911637.","journal-title":"Int J Mol Sci"},{"key":"3030_CR69","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s12035-014-8772-z","volume":"51","author":"E Benito","year":"2015","unstructured":"Benito E, Barco A. The neuronal activity-driven transcriptome. Mol Neurobiol. 2015;51:1071\u201388. https:\/\/doi.org\/10.1007\/s12035-014-8772-z.","journal-title":"Mol Neurobiol"},{"key":"3030_CR70","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1371\/journal.pone.0118510","volume":"75","author":"G Beaudry","year":"2000","unstructured":"Beaudry G, Langlois MC, Weppe I, Rouillard C, Levesque D. Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. J Neurochem. 2000;75:1694\u2013702. https:\/\/doi.org\/10.1371\/journal.pone.0118510.","journal-title":"J Neurochem"},{"key":"3030_CR71","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1124\/jpet.104.080184","volume":"313","author":"J Maheux","year":"2005","unstructured":"Maheux J, Ethier I, Rouillard C, Levesque D. Induction patterns of transcription factors of the nur family (nurr1, nur77, and nor-1) by typical and atypical antipsychotics in the mouse brain: implication for their mechanism of action. J Pharmacol Exp Ther. 2005;313:460\u201373. https:\/\/doi.org\/10.1124\/jpet.104.080184.","journal-title":"J Pharmacol Exp Ther"},{"key":"3030_CR72","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.npp.1300318","volume":"29","author":"I \u00c9thier","year":"2004","unstructured":"\u00c9thier I, Beaudry G, Hilaire MST, Milrandt J, Rouillard C, Levesque D. The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic- induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology. 2004;29:335\u201346. https:\/\/doi.org\/10.1038\/sj.npp.1300318.","journal-title":"Neuropsychopharmacology"},{"key":"3030_CR73","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/s41593-023-01390-9","volume":"26","author":"S Yun","year":"2023","unstructured":"Yun S, Yang B, Anair JD, Martin MM, Fleps SW, Pamucku A, et al. Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons. Nat Neurosci. 2023;26:1417\u201328. https:\/\/doi.org\/10.1038\/s41593-023-01390-9.","journal-title":"Nat Neurosci"},{"key":"3030_CR74","doi-asserted-by":"publisher","first-page":"e0179082","DOI":"10.1371\/journal.pone.0179082","volume":"12","author":"M Rassu","year":"2017","unstructured":"Rassu M, Del Giudice MG, Sanna S, Taymans JM, Morari M, Brugnoli A, et al. Role of LRRK2 in the regulation of dopamine receptor trafficking. PLoS ONE. 2017;12:e0179082. https:\/\/doi.org\/10.1371\/journal.pone.0179082.","journal-title":"PLoS ONE"},{"key":"3030_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-5-14","volume":"5","author":"E Kandel","year":"2012","unstructured":"Kandel E. The molecular biology of memory: cAMP, PKA, CREB-1, CREB-2, and CPEB. Mol Brain. 2012;5:14. https:\/\/doi.org\/10.1186\/1756-6606-5-14.","journal-title":"Mol Brain"},{"key":"3030_CR76","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2018.07.028","volume":"174","author":"A Saunders","year":"2018","unstructured":"Saunders A, Macosko EZ, Wysoker A, Goldman M, Krienen FM, de Rivera H, et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell. 2018;174:1015\u201330. https:\/\/doi.org\/10.1016\/j.cell.2018.07.028.","journal-title":"Cell."},{"key":"3030_CR77","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670\u201383. https:\/\/doi.org\/10.1001\/jama.2014.3654.","journal-title":"JAMA"},{"key":"3030_CR78","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki J, Meisner R, Diaz D, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med. 2022;14:eabj2658. https:\/\/doi.org\/10.1126\/scitranslmed.abj2658.","journal-title":"Sci Transl Med"},{"key":"3030_CR79","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","volume":"8","author":"HT Zhao","year":"2017","unstructured":"Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, et al. LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model. Mol Ther Nucleic Acids. 2017;8:508\u201319. https:\/\/doi.org\/10.1016\/j.omtn.2017.08.002.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3030_CR80","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-020-0893-5","volume":"26","author":"N Whiffin","year":"2020","unstructured":"Whiffin N, Armean IM, Kleinman A, Marshall JL, Minikel EV, Goodrich JK, et al. The effect of LRRK2 loss-of-function variants in humans. Nat Med. 2020;26:869\u201377. https:\/\/doi.org\/10.1038\/s41591-020-0893-5.","journal-title":"Nat Med"},{"key":"3030_CR81","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.122881","volume":"60","author":"O Agid","year":"2023","unstructured":"Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action a hypothesis tested and rejected. Arch Gen Psychiatry. 2023;60:1228\u201335. https:\/\/doi.org\/10.1001\/archpsyc.60.12.122881.","journal-title":"Arch Gen Psychiatry"},{"key":"3030_CR82","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","volume":"57","author":"S Leucht","year":"2005","unstructured":"Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57:1543\u20139. https:\/\/doi.org\/10.1016\/j.biopsych.2005.02.023.","journal-title":"Biol Psychiatry"},{"key":"3030_CR83","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature02033","volume":"425","author":"S Gong","year":"2003","unstructured":"Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature. 2003;425:917\u201325. https:\/\/doi.org\/10.1038\/nature02033.","journal-title":"Nature"},{"key":"3030_CR84","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/nn.2862","volume":"14","author":"EP Bello","year":"2011","unstructured":"Bello EP, Mateo Y, Gelman DM, Noain D, Shin JH, Low MJ, et al. Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors. Nat Neurosci. 2011;14:1033\u20138. https:\/\/doi.org\/10.1038\/nn.2862.","journal-title":"Nat Neurosci"},{"key":"3030_CR85","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.biopsych.2020.12.022","volume":"89","author":"M Wu","year":"2021","unstructured":"Wu M, Minkowicz S, Dumrongprechachan V, Hamilton P, Kozorovitskiy Y. Ketamine rapidly enhances glutamate-evoked dendritic spinogenesis in medial prefrontal cortex through dopaminergic mechanisms. Biol Psychiatry. 2021;89:1096\u2013105. https:\/\/doi.org\/10.1016\/j.biopsych.2020.12.022.","journal-title":"Biol Psychiatry"},{"key":"3030_CR86","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neuron.2023.10.002","volume":"112","author":"M Wu","year":"2024","unstructured":"Wu M, Zhang X, Feng S, Freda SN, Kumari P, Dumrongprechachan V, et al. Dopamine pathways mediating affective state transitions after sleep loss. Neuron. 2024;112:141\u201354. https:\/\/doi.org\/10.1016\/j.neuron.2023.10.002. e8","journal-title":"Neuron"},{"key":"3030_CR87","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.08.439091","volume":"12","author":"V Dumrongprechachan","year":"2021","unstructured":"Dumrongprechachan V, Salisbury RB, Soto G, Kumar M, MacDonald ML, Kozorovitskiy Y. Cell type and subcellular compartment specific APEX2 proximity labeling proteomics in the mouse brain. Nat Commun. 2021;12:4855. https:\/\/doi.org\/10.1101\/2021.04.08.439091.","journal-title":"Nat Commun"},{"key":"3030_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/1475-925X-2-13","volume":"17","author":"T Pologruto","year":"2023","unstructured":"Pologruto T, Sabatini BL, Svodoba K. ScanImage: flexible software for operating laser scanning microscopes. Biomed Eng Online. 2023;17:2. https:\/\/doi.org\/10.1186\/1475-925X-2-13.","journal-title":"Biomed Eng Online"},{"key":"3030_CR89","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard A, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u2013W97. https:\/\/doi.org\/10.1093\/nar\/gkw377.","journal-title":"Nucleic Acids Res"},{"key":"3030_CR90","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/bioinformatics\/btab806","volume":"38","author":"Z Gu","year":"2022","unstructured":"Gu Z, Hubschmann D. Make interactive complex heatmaps in R. Bioinformatics. 2022;38:1460\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btab806.","journal-title":"Bioinformatics"},{"key":"3030_CR91","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1002\/cpns.63","volume":"87","author":"L Erben","year":"2019","unstructured":"Erben L, Buonanno A. Detection and quantification of multiple RNA sequences using emerging ultrasensitive fluorescent in situ hybridization techniques. Curr Protoc Neurosci. 2019;87:e63. https:\/\/doi.org\/10.1002\/cpns.63.","journal-title":"Curr Protoc Neurosci"},{"key":"3030_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-04344-9","volume":"22","author":"DR Stirling","year":"2021","unstructured":"Stirling DR, Swain-Bowden MJ, Lucas AM, Carpenter A, Goodman A, Cimini BA. CellProfiler 4: improvements in speed, utility, and usability. BMC Bioinformatics. 2021;22:433. https:\/\/doi.org\/10.1186\/s12859-021-04344-9.","journal-title":"BMC Bioinformatics"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03030-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03030-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03030-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T15:41:35Z","timestamp":1757950895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03030-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3030"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03030-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.06.597594","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All mouse experiments were approved by Northwestern University Animal Care and Use Committee (approved protocol numbers IS00019801, and IS00030531).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}